Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews · Haematology

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 50%High 1 · 50%

OS (at 3 years) · newly diagnosed or relapsed patients with CLL

The intervention leads to lower OS (at 3 years) (high certainty).

1 finding from 1 review

PFS (at 3 years) · newly diagnosed or relapsed patients with CLL

The intervention probably leads to lower PFS (at 3 years) (moderate certainty).

1 finding from 1 review

Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia 2012 · Cochrane Headline outcomes only
HR 0.64 [0.55, 0.74]
3 studies · 1421 participants
Moderate